Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 10
Submit an article Journal homepage
242
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS)

Jean M. G. Sabilea Internal Medicine Residency Program, Oregon Health & Science University, Portland, OR, USAView further author information
,
Andy Kaempfb Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USAView further author information
,
Kaitlyn Tomicc Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USAView further author information
,
Gurusidda P. Manuc Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USAView further author information
,
Ronan Swordsc Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USAView further author information
&
Yazan Migdadyc Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USACorrespondence[email protected]
View further author information
Pages 1689-1694 | Received 24 Jan 2023, Accepted 24 Jun 2023, Published online: 13 Jul 2023

References

  • Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(11):1399–1420. doi:10.1002/ajh.25950
  • Haferlach T. The molecular pathology of myelodysplastic syndrome. Pathobiology. 2019;86(1):24–29. doi:10.1159/000488712
  • Nazha A. Does mutational burden add to other prognostic factors in MDS? Best Pract Res Clin Haematol. 2019;32(4):101098. doi:10.1016/j.beha.2019.101098
  • Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376–3382. doi:10.1200/JCO.2011.40.7379
  • Daver N, Naqvi K, Jabbour E, et al. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol. 2014;89(5):509–516. doi:10.1002/ajh.23675
  • DeZern AE. Lower risk but high risk. Hematology Am Soc Hematol Educ Program. 2021;2021(1):428–434. doi:10.1182/hematology.2021000277
  • Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evidence. 2022;1(7):EVIDoa2200008. doi:10.1056/EVIDoa2200008
  • Sauta E, Robin M, Bersanelli M, et al. Real-world validation of molecular International Prognostic Scoring System for myelodysplastic syndromes. J Clin Oncol. 2023;41(15):2827–2842. doi:10.1200/JCO.22.01784
  • Baer C, Huber S, Hutter S, et al. Risk prediction in MDS: independent validation of the IPSS-M—ready for routine? Leukemia. 2023;37(4):938–941. doi:10.1038/s41375-023-01831-1
  • Wu J, Zhang Y, Qin T, et al. IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes. Exp Hematol Oncol. 2022;11(1):73. doi:10.1186/s40164-022-00328-4
  • Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–2506. doi:10.1056/NEJMoa1013343
  • Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–247. doi:10.1038/leu.2013.336
  • Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO Classification-Based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the Revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29(7):1502–1513. doi:10.1038/leu.2015.55
  • Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. doi:10.1182/blood-2012-03-420489
  • Voso MT, Fenu S, Latagliata R, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional. J Clin Oncol. 2013;31(21):2671–2677. doi:10.1200/JCO.2012.48.0764
  • Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol. 2013;40(6):666–675. doi:10.1053/j.seminoncol.2013.09.013
  • Greco M, D'Alò F, Scardocci A, et al. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells Mol Dis. 2010;45(3):181–185. doi:10.1016/j.bcmd.2010.05.008
  • Ok CY, Patel KP, Garcia-Manero G, et al. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015;39(3):348–354. doi:10.1016/j.leukres.2014.12.006
  • Voso MT, D'Alò F, Greco M, et al. Epigenetic changes in therapy-related MDS/AML. Chem Biol Interact. 2010;184(1–2):46–49. doi:10.1016/j.cbi.2009.10.013
  • Hunter AM, Komrokji RS, Yun S, et al. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021;5(4):1017–1028. doi:10.1182/bloodadvances.2020003508

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.